Trial Profile

A retrospective, real-world study of safety and efficacy of RBX2660 in patients with Clostridium-difficile-infections

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RBX 2660 (Primary)
Indications Clostridium difficile infections
Focus Adverse reactions; Therapeutic Use

Most Recent Events

01 Nov 2021 New trial record
27 Oct 2021 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
25 Oct 2021 According to Ferring Pharmaceuticals media release, data of this study presented at the American College of Gastroenterology 2021 annual congress.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com